dianahsieh Posted August 31, 2015 Report Share Posted August 31, 2015 My latest Forbes piece is now out: “The Positive Value of Negative Drug Trials“. I discuss the unfortunate bias against publishing “negative” scientific results that show a drug doesn’t have much clinical benefit, and why it’s in the self-interest of drug companies to still report these. In particular, I highlighted two interesting facts: 1) Most drug trial results are still not being reported to a central registry. 2) Negative results funded by private industry (e.g., pharmaceutical companies) are more likely to be reported than from government-funded research. Fortunately, free market incentives are driving more drug companies towards full disclosure of both positive and negative study results — which will benefit patients. For more details, read the full text of “The Positive Value of Negative Drug Trials“. Link to Original Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.